Streetbeat News

Stock Prices

CROX

BofA Securities analyst Christopher Nardone initiated coverage of Crocs, Inc. (NASDAQ:CROX) with a Buy rating and a $128 price target. Crocs has seen a 25% annual sales growth since 2019, popular among Gen Z, and is expected to maintain strong momentum. Growth drivers include new products, collaborations, gains in the sandals segment, a solid kid's business, and expansion in Asia-Pacific. The company is also addressing strategic issues from the HD brand post-acquisition in February 2022.

Portfolio Pulse from Priya Nigam

December 12, 2023 | 5:10 pm

PTPI

Petros Pharmaceuticals' stock is trading higher following the completion of a Human Factors Study for a technology component designed to improve patient access to its erectile dysfunction drug, STENDRA.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 5:09 pm

GO

Grocery Outlet's stock is trading lower following the announcement of a CFO transition and the reaffirmation of its Q4 and FY23 guidance. Additionally, Goldman Sachs downgraded Grocery Outlet from Buy to Sell and reduced the price target from $33 to $24.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 5:09 pm

BA

EADSY

Avolon, an aircraft leasing company, has placed an order for 100 A321neo aircraft from Airbus SE (OTC:EADSY) and 40 737 MAX aircraft from Boeing Co (NYSE:BA). The orders, valued at $12.95 billion for Airbus and $4.9 billion for Boeing, are scheduled for delivery in 2032 and are subject to shareholder approval. Avolon's fleet will increase to 1037 aircraft, and the new aircraft are expected to reduce fuel use and carbon emissions by up to 20%. Avolon's CEO expressed confidence in their balance sheet and relationships with Airbus and Boeing. Boeing highlighted Avolon's repeat order as a sign of confidence in the 737-8. BA shares rose 0.67% to $249.75.

Portfolio Pulse from Shivani Kumaresan

December 12, 2023 | 5:06 pm

SNDX

Syndax Pharmaceuticals (NASDAQ:SNDX) presented positive data from the AUGMENT-101 trial of revumenib for relapsed/refractory KMT2Ar acute leukemia at the ASH Meeting. The trial met its primary endpoint, showing a 63% overall response rate and a median overall survival of 8.0 months. The treatment was well tolerated with low discontinuation rates. Syndax plans to submit a New Drug Application for revumenib to the FDA by year-end.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 5:04 pm

ADTX

Aditxt, Inc. shares have risen following the announcement of their agreement to acquire Evofem Biosciences, indicating a strategic move that could potentially expand Aditxt's product portfolio and market presence.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 5:02 pm

SQM

Over the past 3 months, 5 analysts have provided their opinions on Sociedad Quimica Y Minera (NYSE:SQM), with 4 being somewhat bullish and 1 somewhat bearish. The average 12-month price target for SQM is $71.4, with a high of $84.00 and a low of $59.00. This target has decreased by 13.63% from the previous target of $82.67. Analyst ratings are based on company data, financial statements, and insider information.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 5:00 pm

BKNG

Over the past 3 months, 12 Wall Street analysts have provided ratings for Booking Holdings (NASDAQ:BKNG), with an average price target of $3552.25, representing an upside from the current price of $3385. The distribution of ratings is 4 bullish, 6 somewhat bullish, and 2 indifferent, with no bearish ratings. The current average price target has increased by 5.3% from the previous target of $3373.38.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 5:00 pm

CME

Over the past 20 years, CME Group (NASDAQ:CME) has delivered an average annual return of 14.49%, outperforming the market. A $1000 investment in CME stock two decades ago would now be worth $15,314.90. CME Group currently has a market cap of $77.39 billion.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 5:00 pm

MS

Morgan Stanley (NYSE:MS) has outperformed the market with an average annual return of 16.07% over the past 5 years. A $100 investment in MS five years ago would now be worth $210.44. The company's current market capitalization stands at $135.98 billion.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 5:00 pm